Prospective, Non-interventional Study to Evaluate Immunogenicity of AryoSeven

Inclusion Criteria: * Patients with Hemophilia A or B with inhibitors, Factor VII Deficiency, Glanzmann's thrombasthenia * Treated with AryoSeven in the daily practice, * Signed informed consent (parents for children). * an immunogenicity test negative, performed at the earliest time after NovoSeven was no longer available in Iran. Patients who do not have a previous negative immunogenicity test should be enrolled if negative at immunogenicity test performed during screening for this study. Exclusion Criteria: * Patients who received NovoSeven for any indication at any time before inclusion in the study, until an immunogenicity test excluded the development of immunogenicity related to NovoSeven. * Parallel participation in another experimental drug trial. * Parallel participation in another marketed drug trial (except for AryoSeven) that may affect the immunogenicity endpoint of the study.